Repare Therapeutics IncNASDAQ:RPTX
- LAST PRICE3.2000
- TODAY'S CHANGE (%)0.0500 (1.5873%)
- Bid / Lots3.1100/ 4
- Ask / Lots3.5400/ 1
- Open / Previous Close3.1800 / 3.1500
- Day Range
- 52 Week Range
- Volume71,408
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RPTX |
|---|---|---|
| 09:41 ET | 100 | 3.18 |
| 09:43 ET | 600 | 3.21 |
| 09:52 ET | 100 | 3.21 |
| 09:56 ET | 500 | 3.205 |
| 10:01 ET | 100 | 3.2 |
| 10:06 ET | 100 | 3.21 |
| 10:10 ET | 200 | 3.21 |
| 10:14 ET | 100 | 3.21 |
| 10:15 ET | 100 | 3.18 |
| 10:37 ET | 254 | 3.23 |
| 10:46 ET | 13525 | 3.2 |
| 11:02 ET | 800 | 3.17 |
| 11:06 ET | 400 | 3.19 |
| 11:08 ET | 200 | 3.17 |
| 11:09 ET | 400 | 3.19 |
| 11:13 ET | 300 | 3.19 |
| 11:18 ET | 100 | 3.2075 |
| 11:20 ET | 300 | 3.19 |
| 11:26 ET | 700 | 3.19 |
| 11:29 ET | 100 | 3.21 |
| 11:36 ET | 300 | 3.21 |
| 11:38 ET | 400 | 3.2 |
| 11:42 ET | 200 | 3.2075 |
| 11:44 ET | 1400 | 3.21 |
| 11:51 ET | 100 | 3.22 |
| 11:58 ET | 817 | 3.2 |
| 12:03 ET | 300 | 3.2 |
| 12:05 ET | 1000 | 3.1901 |
| 12:14 ET | 200 | 3.205 |
| 12:18 ET | 300 | 3.21 |
| 12:20 ET | 400 | 3.19 |
| 12:27 ET | 300 | 3.2 |
| 12:34 ET | 1300 | 3.2 |
| 12:41 ET | 200 | 3.19 |
| 12:45 ET | 100 | 3.19 |
| 12:50 ET | 100 | 3.19 |
| 12:56 ET | 100 | 3.19 |
| 12:59 ET | 600 | 3.19 |
| 01:15 ET | 300 | 3.2 |
| 01:17 ET | 900 | 3.2 |
| 01:19 ET | 1600 | 3.19 |
| 01:21 ET | 300 | 3.2 |
| 01:24 ET | 100 | 3.2 |
| 01:26 ET | 820 | 3.19 |
| 01:28 ET | 1000 | 3.1999 |
| 01:30 ET | 500 | 3.185 |
| 01:33 ET | 100 | 3.17 |
| 01:37 ET | 700 | 3.17 |
| 01:44 ET | 100 | 3.19 |
| 01:48 ET | 100 | 3.17 |
| 01:51 ET | 100 | 3.17 |
| 01:55 ET | 300 | 3.17 |
| 02:04 ET | 500 | 3.17 |
| 02:09 ET | 100 | 3.16 |
| 02:18 ET | 100 | 3.16 |
| 02:27 ET | 610 | 3.14 |
| 02:36 ET | 400 | 3.13 |
| 02:40 ET | 268 | 3.11 |
| 02:49 ET | 100 | 3.12 |
| 02:54 ET | 1100 | 3.14 |
| 02:56 ET | 300 | 3.1498 |
| 03:02 ET | 800 | 3.15 |
| 03:03 ET | 500 | 3.14 |
| 03:20 ET | 100 | 3.16 |
| 03:25 ET | 100 | 3.14 |
| 03:32 ET | 100 | 3.15 |
| 03:34 ET | 900 | 3.135 |
| 03:36 ET | 200 | 3.15 |
| 03:38 ET | 100 | 3.15 |
| 03:39 ET | 304 | 3.16 |
| 03:41 ET | 1100 | 3.17 |
| 03:43 ET | 703 | 3.17 |
| 03:45 ET | 300 | 3.17 |
| 03:48 ET | 1200 | 3.17 |
| 03:50 ET | 600 | 3.19 |
| 03:52 ET | 300 | 3.19 |
| 03:54 ET | 2900 | 3.18 |
| 03:56 ET | 2568 | 3.18 |
| 03:57 ET | 1203 | 3.19 |
| 03:59 ET | 1700 | 3.2 |
Yesterday
*DJ Repare Therapeutics Names Steven H. Stein to Board, from 8 hours ago by Dow Jones
8 hours ago by Dow JonesRepare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors, from 8 hours ago by Dow Jones
8 hours ago by Dow Jones
Mar 28, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Repare Therapeutics Inc | 132.9M | -1.4x | --- |
Precision BioSciences Inc | 67.2M | -0.9x | --- |
Champions Oncology Inc | 68.8M | -7.0x | --- |
AVITA Medical Inc | 213.4M | -6.1x | --- |
Genfit SA | 168.5M | -5.6x | --- |
Innate Pharma SA | 188.6M | -24.4x | --- |
Company Information
Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on the development of synthetic lethality (SL)-based therapies for patients with cancer. The Company is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. It uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Company’s initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor.
Contact Information
- Headquarters
- 7210 Frederick-Banting, Suite 100ST-LAURENT, QC, Canada H4S 2A1
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Thomas Civik
- President, Chief Executive Officer, Director
- Lloyd Segal
- Chief Financial Officer, Executive Vice President
- Steve Forte
- Executive Vice President, Chief Scientific Officer
- Michael Zinda
- Executive Vice President, Chief Medical Officer
- Maria Koehler
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $132.9M |
|---|---|
Revenue (TTM) | $51.1M |
Shares Outstanding | 42.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.68 |
EPS | $-2.23 |
Book Value | $5.03 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | 2.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -227.30% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
